Abogen Biosciences Showcases AI-Driven Ionizable Lipid Design and In Vitro/In Vivo Translation Strategies at the 5th LNP Formulation & Process Development Summit
Abogen
Nucleic Acid Drug Developer
Dr. Ying Bo, Founder, Chairman and CEO of Abogen, was invited to attend the event held in Boston, USA from April 6 to 8.5th LNP Formulation & Process Development Summit。
The LNP Formulation and Process Development Summit is one of the most influential industry events in the global lipid nanoparticle (LNP) field, focusing on overcoming key bottlenecks in LNP technology from laboratory research to commercial production. As a benchmark for the industry, the conference brings together top global pharmaceutical companies, biotechnology firms, and research institutions, including AstraZeneca, Sanofi, GSK, Pfizer, and Merck & Co.
The conference focuses on three core areas: analytical development and characterization, formulation and delivery, and process development and production. It shares nearly 50 data-driven case studies to help overcome key bottlenecks such as LNP targeted delivery, stability, and process scaling, serving as a crucial platform for understanding global LNP technology trends and expanding international cooperation.
Fireside Chat
Fireside Chat
Subject:Bridging In Vitro/In Vivo Translation by Overcoming Limitations of Potency Assays & Animal Models to Accelerate LNP Clinical Progress
Time:April 7, 2026 1:30 PM (EDT)
Summary:
① What key factors should be considered when selecting cell lines to develop bioassays that accurately predict the in vivo efficacy of LNPs?
② How to design a quantitative assay method to measure the expression levels of relevant cargoes in order to understand biological activity?
③ Which animal models can provide the most reliable assessment of LNP efficacy? How to better address interspecies differences in biodistribution and protein corona formation?
Special Lecture
Keynote Presentation
Subject:An "Irrational" Ionizable Lipid Design Approach Based on Machine Learning Models
Time:April 7, 2026 3:30 PM (EDT)
Summary:
① The traditional design of ionizable lipids is based on the Structure-Activity Relationship (SAR) model, with limited innovative structures; SM-102 and Lipid-5 remain benchmarks in the field of mRNA delivery.
② Abogen has established a library of ionizable lipids with in vivo testing results, which is used to train internal machine learning models. As the model becomes increasingly mature, we have gradually shifted from rational design to an AI-driven approach for generating ionizable lipids.
③ AI-driven lipid generators have created some truly innovative structures, which not only perform better in terms of efficiency and safety but also have the potential to address the inherent limitations of LNPs in repeated intravenous administration.
As a top platform integrating cutting-edge breakthroughs, strategic cooperation, and industry insights, this year's conference will accelerate the translation of LNP technology from concept to clinical application, promoting the availability of safe and effective LNP therapies for more patients. Abogen's deep involvement and sharing of frontier technologies not only highlight its leading position in the global LNP innovation field but also reflect the significant influence of Chinese mRNA companies on the international stage.
For more information, please visit the official website:
About Us
Abogen Biosciences (referred to as "Abogen") is an innovative biopharmaceutical company specializing in the research and development of messenger ribonucleic acid (mRNA) drugs. The company owns industry-leading, proprietary intellectual property rights over its mRNA and nanodelivery technology platforms. It is one of the few mRNA drug research and development enterprises in China with complete value chain capabilities, covering all aspects from mRNA design, formulation development, to large-scale production. The company has established a rich product pipeline, spanning multiple fields including cancer immunotherapy, autoimmune diseases, and infectious disease prevention.
